scorecardresearchBrokerages bullish on Glenmark Pharma despite muted Q2 earnings. Here's why

Brokerages bullish on Glenmark Pharma despite muted Q2 earnings. Here's why

Updated: 23 Nov 2022, 11:39 AM IST
TL;DR.
  • Glenmark Pharma has corrected about 20.44 percent and Nifty Pharma has lost around 9 percent in 2022 so far.
Despite the stock falling over 20 percent YTD and a muted Q2FY23, brokerages and analysts are bullish on Glenmark Pharma.

Despite the stock falling over 20 percent YTD and a muted Q2FY23, brokerages and analysts are bullish on Glenmark Pharma.